HUE046788T2 - Gyógyászati készítmény rák kezelésére és/vagy megelõzésére - Google Patents
Gyógyászati készítmény rák kezelésére és/vagy megelõzéséreInfo
- Publication number
- HUE046788T2 HUE046788T2 HUE13751159A HUE13751159A HUE046788T2 HU E046788 T2 HUE046788 T2 HU E046788T2 HU E13751159 A HUE13751159 A HU E13751159A HU E13751159 A HUE13751159 A HU E13751159A HU E046788 T2 HUE046788 T2 HU E046788T2
- Authority
- HU
- Hungary
- Prior art keywords
- cancer
- prevention
- treatment
- pharmaceutical composition
- pharmaceutical
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012035342 | 2012-02-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE046788T2 true HUE046788T2 (hu) | 2020-03-30 |
Family
ID=49005808
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE13751159A HUE046788T2 (hu) | 2012-02-21 | 2013-02-21 | Gyógyászati készítmény rák kezelésére és/vagy megelõzésére |
Country Status (17)
Country | Link |
---|---|
US (1) | US9260513B2 (hu) |
EP (1) | EP2818481B1 (hu) |
JP (1) | JP6187257B2 (hu) |
KR (1) | KR102005308B1 (hu) |
CN (1) | CN104114581B (hu) |
AU (1) | AU2013223137B2 (hu) |
BR (1) | BR112014021099A2 (hu) |
CA (1) | CA2864999C (hu) |
DK (1) | DK2818481T3 (hu) |
ES (1) | ES2749672T3 (hu) |
HU (1) | HUE046788T2 (hu) |
IN (1) | IN2014KN01714A (hu) |
MX (1) | MX363136B (hu) |
PL (1) | PL2818481T3 (hu) |
PT (1) | PT2818481T (hu) |
RU (1) | RU2639522C2 (hu) |
WO (1) | WO2013125630A1 (hu) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5644110B2 (ja) | 2008-08-05 | 2014-12-24 | 東レ株式会社 | 癌の検出方法 |
RU2498819C2 (ru) | 2008-08-05 | 2013-11-20 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и профилактики злокачественных опухолей |
JP5906739B2 (ja) * | 2010-02-04 | 2016-04-20 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
HUE030130T2 (hu) * | 2011-08-04 | 2017-04-28 | Toray Industries | Gyógyászati készítmény hasnyálmirigyrák kezelésére és/vagy megelõzésére |
JP6094220B2 (ja) * | 2011-08-04 | 2017-03-15 | 東レ株式会社 | 膵臓癌の検出方法 |
PL2818483T3 (pl) | 2012-02-21 | 2018-01-31 | Toray Industries | Kompozycja lecznicza do leczenia i/lub zapobiegania nowotworowi |
PL2832366T3 (pl) | 2012-03-30 | 2018-04-30 | Toray Industries, Inc. | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania rakowi pęcherzyka żółciowego |
AU2013241036B2 (en) * | 2012-03-30 | 2017-07-20 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of liver cancer |
PT2876446T (pt) | 2012-07-19 | 2019-03-25 | Toray Industries | Método para deteção de cancro |
BR112015001100A2 (pt) | 2012-07-19 | 2018-03-27 | Toray Industries, Inc. | método de detecção de câncer |
TR201819812T4 (tr) | 2013-08-09 | 2019-01-21 | Toray Industries | Kanserin Tedavisi Ve/Veya Önlenmesi Amacına Yönelik Farmasötik Bileşim |
KR102726248B1 (ko) | 2016-07-07 | 2024-11-05 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항체-애쥬번트 접합체 |
JP7206590B2 (ja) | 2016-10-28 | 2023-01-18 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
US20210121562A1 (en) | 2018-03-30 | 2021-04-29 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
AU2020241686A1 (en) | 2019-03-15 | 2021-11-04 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting HER2 |
MX2021015221A (es) | 2019-06-13 | 2022-03-17 | Bolt Biotherapeutics Inc | Compuestos de aminobenzazepina, inmunoconjugados y usos de estos. |
US20220347310A1 (en) | 2019-09-30 | 2022-11-03 | Bolt Biotherapeutics, Inc. | Amide-linked, aminobenzazepine immunoconjugates, and uses thereof |
JP2022553702A (ja) | 2019-10-25 | 2022-12-26 | ボルト バイオセラピューティクス、インコーポレーテッド | チエノアゼピン、イムノコンジュゲート、及びそれらの使用 |
WO2021182574A1 (ja) | 2020-03-12 | 2021-09-16 | 東レ株式会社 | 癌の治療及び/又は予防のための医薬品 |
JPWO2021182570A1 (hu) | 2020-03-12 | 2021-09-16 | ||
WO2021182573A1 (ja) | 2020-03-12 | 2021-09-16 | 東レ株式会社 | 癌の治療及び/又は予防のための医薬品 |
WO2021182571A1 (ja) | 2020-03-12 | 2021-09-16 | 東レ株式会社 | 癌の治療及び/又は予防のための医薬品 |
KR20220153615A (ko) | 2020-03-12 | 2022-11-18 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
US20230293716A1 (en) | 2020-05-08 | 2023-09-21 | Bolt Biotherapeutics, Inc. | Elastase-substrate, peptide linker immunoconjugates, and uses thereof |
AU2021326516A1 (en) | 2020-08-13 | 2023-04-13 | Bolt Biotherapeutics, Inc. | Pyrazoloazepine immunoconjugates, and uses thereof |
MX2023014498A (es) | 2021-06-23 | 2024-01-25 | Toray Industries | Medicamento para el tratamiento y/o prevencion de cancer. |
EP4360649A1 (en) | 2021-06-23 | 2024-05-01 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
EP4378476A1 (en) | 2021-07-27 | 2024-06-05 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
EP4378478A1 (en) | 2021-07-27 | 2024-06-05 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
JPWO2023008461A1 (hu) | 2021-07-27 | 2023-02-02 | ||
KR20240051956A (ko) | 2021-09-03 | 2024-04-22 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
US20250000995A1 (en) | 2021-10-29 | 2025-01-02 | Bolt Biotherapeutics, Inc. | Tlr agonist immunoconjugates with cysteine-mutant antibodies, and uses thereof |
JPWO2024005123A1 (hu) | 2022-06-30 | 2024-01-04 | ||
AU2023329563A1 (en) | 2022-08-24 | 2025-02-27 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
AU2023329558A1 (en) | 2022-08-24 | 2025-02-27 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
AU2023329564A1 (en) | 2022-08-24 | 2025-02-27 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
WO2024048542A1 (ja) | 2022-08-30 | 2024-03-07 | 東レ株式会社 | 癌の治療及び/又は予防のための医薬品 |
WO2024048541A1 (ja) | 2022-08-30 | 2024-03-07 | 東レ株式会社 | 癌の治療及び/又は予防のための医薬品 |
WO2024173387A1 (en) | 2023-02-14 | 2024-08-22 | Bolt Biotherapeutics, Inc. | Aza-benzazepine immunoconjugates, and uses thereof |
WO2024186626A1 (en) | 2023-03-03 | 2024-09-12 | Bolt Biotherapeutics, Inc. | Aza-bicyclic sting agonist immunoconjugates, and uses thereof |
WO2025058000A1 (ja) * | 2023-09-13 | 2025-03-20 | 東レ株式会社 | 癌の治療、予防及び/又は診断用医薬組成物 |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
KR100261941B1 (ko) | 1994-07-13 | 2000-07-15 | 나가야마 오사무 | 사람의 인터루킨-8에 대한 재구성 사람항체 |
US5698396A (en) | 1995-06-07 | 1997-12-16 | Ludwig Institute For Cancer Research | Method for identifying auto-immunoreactive substances from a subject |
FR2761994B1 (fr) | 1997-04-11 | 1999-06-18 | Centre Nat Rech Scient | Preparation de recepteurs membranaires a partir de baculovirus extracellulaires |
ES2364266T3 (es) | 1998-04-03 | 2011-08-30 | Chugai Seiyaku Kabushiki Kaisha | Anticuerpo humanizado hacia el factor tisular humano (tf) y procedimiento para construir el anticuerpo humanizado. |
US20030118599A1 (en) | 1999-04-02 | 2003-06-26 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
RU2234942C2 (ru) | 1998-07-14 | 2004-08-27 | Корикса Корпорейшн | Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид |
EP1870466A3 (en) | 1998-07-14 | 2008-03-19 | Corixa Corporation | Compositions and methods for therapy and diagnosis of prostate cancer |
US6969518B2 (en) | 1998-12-28 | 2005-11-29 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
US6335170B1 (en) | 1999-02-22 | 2002-01-01 | Torben F. Orntoft | Gene expression in bladder tumors |
US6444425B1 (en) | 1999-04-02 | 2002-09-03 | Corixa Corporation | Compounds for therapy and diagnosis of lung cancer and methods for their use |
EP1187915A2 (en) | 1999-04-02 | 2002-03-20 | Corixa Corporation | Compounds for therapy and diagnosis of lung cancer and methods for their use |
US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
EP1224285A4 (en) | 1999-10-29 | 2004-12-08 | Human Genome Sciences Inc | 27 HUMAN SECRETED PROTEINS |
US20020006404A1 (en) | 1999-11-08 | 2002-01-17 | Idec Pharmaceuticals Corporation | Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
PL366626A1 (en) | 2000-03-29 | 2005-02-07 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
ES2295228T3 (es) | 2000-11-30 | 2008-04-16 | Medarex, Inc. | Roedores transcromosomicos transgenicos para la preparacion de anticuerpos humanos. |
US7919467B2 (en) | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
US20040029114A1 (en) | 2001-01-24 | 2004-02-12 | Eos Technology, Inc. | Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer |
RU2306952C2 (ru) | 2001-01-31 | 2007-09-27 | Байоджен Айдек Инк. | Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами |
AU2002311787A1 (en) | 2001-03-28 | 2002-10-15 | Zycos Inc. | Translational profiling |
WO2002083070A2 (en) | 2001-04-10 | 2002-10-24 | Corixa Corporation | Compounds for immunotherapy and diagnosis of colon cancer and methods for their use |
AU2002309063B8 (en) | 2001-05-11 | 2008-04-24 | Kyowa Kirin Co., Ltd. | Artificial human chromosome containing human antibody lambda light chain gene |
EP1516049A4 (en) | 2001-05-11 | 2006-01-11 | Corixa Corp | COMPOSITIONS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF LUNG CANCER |
US20030190640A1 (en) | 2001-05-31 | 2003-10-09 | Mary Faris | Genes expressed in prostate cancer |
US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
EP1575480A4 (en) | 2002-02-22 | 2008-08-06 | Genentech Inc | COMPOSITIONS AND METHODS FOR TREATING DISEASES RELATED TO THE IMMUNE SYSTEM |
US20050003390A1 (en) | 2002-05-17 | 2005-01-06 | Axenovich Sergey A. | Targets for controlling cellular growth and for diagnostic methods |
US20040126379A1 (en) | 2002-08-21 | 2004-07-01 | Boehringer Ingelheim International Gmbh | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents |
EP2179742A1 (en) | 2002-11-26 | 2010-04-28 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
WO2004076682A2 (en) | 2003-02-26 | 2004-09-10 | Surromed, Inc. | Targets for controlling cellular growth and for diagnostic methods |
WO2004097051A2 (en) | 2003-04-29 | 2004-11-11 | Wyeth | Methods for diagnosing aml and mds differential gene expression |
EP1639090A4 (en) | 2003-06-09 | 2008-04-16 | Univ Michigan | COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER |
US20070048738A1 (en) | 2003-07-14 | 2007-03-01 | Mayo Foundation For Medical Education And Research | Methods and compositions for diagnosis, staging and prognosis of prostate cancer |
US20050032113A1 (en) | 2003-07-17 | 2005-02-10 | Mitsubishi Pharma Corporation | Membrane protein library for proteome analysis and method for preparing same |
EP2361929A1 (en) | 2004-01-26 | 2011-08-31 | Debiovision Inc. | Neoplasm-specific polypeptides and their use |
PT1735348E (pt) | 2004-03-19 | 2012-07-24 | Imclone Llc | Anticorpo anti-receptor do factor de crescimento humano |
NZ550225A (en) | 2004-03-30 | 2010-11-26 | Glaxo Group Ltd | Immunoglobulins that bind oncostatin and inhibit or block interaction between hOSM and pg130 |
WO2005100998A2 (en) | 2004-04-16 | 2005-10-27 | Europroteome Ag | Membrane markers for use in cancer diagnosis and therapy |
WO2006002378A2 (en) | 2004-06-23 | 2006-01-05 | Avalon Pharmaceuticals | Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods |
JP2008528486A (ja) | 2005-01-21 | 2008-07-31 | ジェネンテック・インコーポレーテッド | Her抗体の一定投薬 |
WO2006089212A2 (en) | 2005-02-18 | 2006-08-24 | Children's Medical Center Corporation | Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin |
CA2602088C (en) | 2005-03-11 | 2021-07-27 | Ciphergen Biosystems, Inc. | Biomarkers for ovarian cancer and endometrial cancer |
JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Herceptin(登録商標)補助療法 |
US8014957B2 (en) | 2005-12-15 | 2011-09-06 | Fred Hutchinson Cancer Research Center | Genes associated with progression and response in chronic myeloid leukemia and uses thereof |
WO2007095186A2 (en) | 2006-02-14 | 2007-08-23 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer |
WO2008073162A2 (en) | 2006-08-17 | 2008-06-19 | Cell Signaling Technology, Inc. | Lysine acetylation sites |
US20080107668A1 (en) | 2006-08-30 | 2008-05-08 | Immunotope, Inc. | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
WO2008031041A2 (en) | 2006-09-07 | 2008-03-13 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Melanoma gene signature |
WO2008059252A2 (en) | 2006-11-15 | 2008-05-22 | Oxford Biomedica (Uk) Limited | Methods and composition fro t cell receptors which recognize 5t4 antigen |
JP5663834B2 (ja) | 2008-03-14 | 2015-02-04 | 東ソー株式会社 | 遺伝子組換え抗体の製造方法 |
CR20180483A (es) | 2008-03-18 | 2018-12-05 | Genentech Inc | COMBINACIONES DE UN CONJUNGADO ANTICUERPO-FÁRMACO ANTI-HER2 Y AGENTES QUIMIOTERAPÉUTICOS (Divisional 11678) |
RU2498819C2 (ru) | 2008-08-05 | 2013-11-20 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и профилактики злокачественных опухолей |
US8454968B2 (en) | 2008-08-05 | 2013-06-04 | Toray Industries, Inc. | Method for inducing immunity with a peptide fragment from human CAPRIN-1 |
JP5644110B2 (ja) | 2008-08-05 | 2014-12-24 | 東レ株式会社 | 癌の検出方法 |
CA2771441C (en) | 2009-08-19 | 2016-10-11 | Merck Patent Gmbh | Antibodies for the detection of integrin complexes in ffpe material |
KR101545914B1 (ko) | 2009-09-22 | 2015-08-20 | 프로바이오겐 아게 | 특수화된 글리칸 구조를 함유하는 분자의 생산 방법 |
RU2418587C1 (ru) * | 2010-01-21 | 2011-05-20 | Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО "НижГМА Росздрава") | Способ лечения злокачественных опухолей головного мозга |
CN102822199B (zh) * | 2010-02-04 | 2014-10-15 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
HUE030102T2 (hu) | 2010-02-04 | 2017-04-28 | Toray Industries | Anti-caprin-1 antitesteket tartalmazó gyógyászati készítmény rák kezelésére és/vagy megelõzésére |
PT2532365T (pt) | 2010-02-04 | 2016-07-28 | Toray Industries | Composição farmacêutica para o tratamento e/ou a prevenção do cancro |
JP5906739B2 (ja) | 2010-02-04 | 2016-04-20 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
WO2011096535A1 (ja) | 2010-02-04 | 2011-08-11 | 東レ株式会社 | 癌の治療及び/又は予防のための医薬品 |
CN102821789B (zh) | 2010-02-04 | 2016-03-02 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
WO2012005550A2 (ko) | 2010-07-08 | 2012-01-12 | 강원대학교산학협력단 | 담낭암 치료용 약제학적 조성물 및 이를 이용한 담낭암의 성장, 전이 억제 및 치료 방법 |
CN103261224B (zh) | 2010-07-26 | 2015-10-07 | 瑟维尔实验室 | 用于肝癌治疗的方法和组合物 |
JP5545105B2 (ja) | 2010-08-04 | 2014-07-09 | 株式会社ジェイテクト | トロイダル型無段変速機のディスクの研磨方法およびトロイダル無段変速機のディスクの研磨装置 |
JP6094220B2 (ja) | 2011-08-04 | 2017-03-15 | 東レ株式会社 | 膵臓癌の検出方法 |
CN103717740B (zh) | 2011-08-04 | 2015-10-21 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
HUE030130T2 (hu) * | 2011-08-04 | 2017-04-28 | Toray Industries | Gyógyászati készítmény hasnyálmirigyrák kezelésére és/vagy megelõzésére |
AU2013241036B2 (en) | 2012-03-30 | 2017-07-20 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of liver cancer |
PL2832366T3 (pl) | 2012-03-30 | 2018-04-30 | Toray Industries, Inc. | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania rakowi pęcherzyka żółciowego |
-
2013
- 2013-02-21 KR KR1020147020831A patent/KR102005308B1/ko active Active
- 2013-02-21 MX MX2014009747A patent/MX363136B/es unknown
- 2013-02-21 BR BR112014021099-3A patent/BR112014021099A2/pt not_active Application Discontinuation
- 2013-02-21 CN CN201380009166.3A patent/CN104114581B/zh active Active
- 2013-02-21 PT PT137511598T patent/PT2818481T/pt unknown
- 2013-02-21 US US14/379,868 patent/US9260513B2/en active Active
- 2013-02-21 PL PL13751159T patent/PL2818481T3/pl unknown
- 2013-02-21 ES ES13751159T patent/ES2749672T3/es active Active
- 2013-02-21 HU HUE13751159A patent/HUE046788T2/hu unknown
- 2013-02-21 DK DK13751159.8T patent/DK2818481T3/da active
- 2013-02-21 IN IN1714KON2014 patent/IN2014KN01714A/en unknown
- 2013-02-21 EP EP13751159.8A patent/EP2818481B1/en active Active
- 2013-02-21 RU RU2014138039A patent/RU2639522C2/ru active
- 2013-02-21 AU AU2013223137A patent/AU2013223137B2/en active Active
- 2013-02-21 CA CA2864999A patent/CA2864999C/en active Active
- 2013-02-21 WO PCT/JP2013/054312 patent/WO2013125630A1/ja active Application Filing
- 2013-02-21 JP JP2013512279A patent/JP6187257B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
BR112014021099A2 (pt) | 2020-12-01 |
DK2818481T3 (da) | 2019-10-14 |
CN104114581A (zh) | 2014-10-22 |
JP6187257B2 (ja) | 2017-08-30 |
PT2818481T (pt) | 2019-10-25 |
EP2818481A4 (en) | 2015-10-07 |
ES2749672T3 (es) | 2020-03-23 |
CN104114581B (zh) | 2018-11-30 |
AU2013223137A1 (en) | 2014-09-11 |
MX2014009747A (es) | 2014-11-14 |
RU2014138039A (ru) | 2016-04-10 |
WO2013125630A1 (ja) | 2013-08-29 |
AU2013223137B2 (en) | 2017-10-19 |
CA2864999A1 (en) | 2013-08-29 |
IN2014KN01714A (hu) | 2015-10-23 |
PL2818481T3 (pl) | 2020-02-28 |
US9260513B2 (en) | 2016-02-16 |
MX363136B (es) | 2019-03-12 |
CA2864999C (en) | 2020-06-30 |
KR20140130670A (ko) | 2014-11-11 |
KR102005308B1 (ko) | 2019-07-30 |
RU2639522C2 (ru) | 2017-12-21 |
JPWO2013125630A1 (ja) | 2015-07-30 |
EP2818481A1 (en) | 2014-12-31 |
EP2818481B1 (en) | 2019-08-07 |
US20150044221A1 (en) | 2015-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL2818481T3 (pl) | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi złośliwemu | |
EP2832365A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF LIVER CANCER | |
HUE036425T2 (hu) | Gyógyászati készítmény epehólyagrák kezelésére és/vagy megelõzésére | |
HUE042081T2 (hu) | Gyógyászati készítmény rák kezelésére és/vagy megelõzésére | |
PL2532365T3 (pl) | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi | |
PL2532743T3 (pl) | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania raka | |
PL2740793T3 (pl) | Kompozycja leku do leczenia i/lub zapobiegania nowotworowi | |
PL2740795T3 (pl) | Kompozycja lekowa do leczenia nowotworu i/lub zapobiegania nowotworowi | |
PL2740798T3 (pl) | Kompozycja leku do leczenia i/lub zapobiegania nowotworom | |
PL2740489T3 (pl) | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania raka trzustki | |
PL2818483T3 (pl) | Kompozycja lecznicza do leczenia i/lub zapobiegania nowotworowi | |
PL2740796T3 (pl) | Kompozycja farmaceutyczna do leczenia nowotworu i/lub zapobiegania nowotworowi | |
HUE039219T2 (hu) | Gyógyászati készítmény rák kezelésére és/vagy megelõzésére | |
HUE044611T2 (hu) | Gyógyászati készítmény rák kezelésére | |
HUE045461T2 (hu) | Gyógyászati készítmény rák kezelésére | |
HUE040012T2 (hu) | Gyógyászati ágens rák kezelésére és/vagy megelõzésére | |
PL2532366T3 (pl) | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi | |
PL2532680T3 (pl) | Kompozycja medyczna do leczenia raka i/lub zapobiegania | |
IL225471B (en) | Preparations for the prevention and treatment of cancer | |
IL238177A0 (en) | Methods and preparations for the treatment of cancer | |
HK1201730A1 (en) | Treatment agent and or prophylactic agent for side effects of cancer drugs | |
ES3009438T3 (en) | Method and pharmaceutical composition for use in the treatment of cancer | |
HK1211221A1 (en) | Formulations for the treatment and prevention of obesity | |
IL221238A0 (en) | Pharmaceutical compositions and methods for the treatment and prevention of cancer |